GKOS250117P55000
- 0.60
- 0.000.00%
Glaukos Newsroom
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $157
Express News | Glaukos Corp : Btig Raises Target Price to $157 From $149
BTIG Sticks to Its Buy Rating for Glaukos (GKOS)
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $175
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $175
(GKOS) - Analyzing Glaukos's Short Interest
Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA
Glaukos Insider Sold Shares Worth $1,502,800, According to a Recent SEC Filing
Insider Sale: Director at $GKOS (GKOS) Sells 10,000 Shares
Glaukos Seeks FDA Approval for Non-Invasive Keratoconus Therapy Epioxa
Express News | Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
The Three-year Returns Have Been Stellar for Glaukos (NYSE:GKOS) Shareholders Despite Underlying Losses Increasing
Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $153
NYSE New 52-Week Highs And Lows
Glaukos (GKOS) Receives a Buy From Stifel Nicolaus
Glaukos Is Maintained at Buy by Truist Securities
Truist Financial Maintains Glaukos(GKOS.US) With Buy Rating, Announces Target Price $185
Glaukos Price Target Raised to $185 From $152 at Truist